Sanofi/Genzyme have withdrawn MabCampath (alemtuzumab) from the European market and established a free distribution programme for B-cell CLL users. In...
Results of the 3C study of Campath - Calcineurin inhibitor reduction and Chronic allograft nephropathy - (alemtuzumab), from Sanofi/Genzyme, which...
A new study shows that combining the chemotherapy drug fludarabine with the monoclonal antibody MabCampath/Campath(alemtuzumab), from Genzyme, significantly increases progression...
Discover the range of therapies currently available and in clinical trials for the treatment of transplant rejection in liver, kidney and lung transplants.